UPDATE: Credit Suisse Initiates Coverage on Evogene on Best-in-Class Position

In a report published Monday, Credit Suisse analyst Christopher S. Parkinson initiated coverage on Evogene Ltd. (NYSE: EVGN ) with an Outperform rating and $25.00 price target. In the report, Credit Suisse noted, “Initiating coverage with an Outperform rating and a $25 TP. We view EVGN as a best-in-class ag